Related Experiment Video
Updated: Apr 17, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.5K
Renal denervation for resistant hypertension and beyond
Luke J Laffin1, George L Bakris1
1Department of Medicine, ASH Comprehensive Hypertension Center, The University of Chicago Medicine Chicago, IL.
Advances in Chronic Kidney Disease
|February 24, 2015
Summary
Many patients with hypertension struggle to reach blood pressure goals, with resistant hypertension affecting millions. Renal denervation therapy shows mixed results, prompting further investigation into its effectiveness for managing high blood pressure.
Area of Science:
- Cardiology
- Nephrology
- Medical Devices
Background:
- Over 75 million people have hypertension, with 36 million not meeting blood pressure goals.
- Resistant hypertension affects 3-6% of hypertensive individuals, often due to inadequate sympathetic nervous system inhibition.
- Current antihypertensive medications are insufficient for many patients, necessitating alternative treatments.
Purpose of the Study:
- To evaluate the efficacy and safety of renal denervation therapy for resistant hypertension.
- To explore the reasons behind the divergent results of renal denervation trials.
- To discuss the future of device-driven approaches for hypertension management.
Main Methods:
- Review of clinical trial data, including SYMPLICITY HTN-2 and SYMPLICITY HTN-3.
- Analysis of factors contributing to blood pressure control failure.
- Discussion of technical advances in targeting renal sympathetic nerves.
Main Results:
- SYMPLICITY HTN-2 demonstrated encouraging efficacy and safety of renal denervation.
- SYMPLICITY HTN-3 yielded disappointing efficacy results, contrasting with earlier findings.
- Inconsistent outcomes highlight the need for further research into renal denervation's role.
Conclusions:
- Renal denervation therapy presents a potential but complex treatment option for resistant hypertension.
- Understanding the discrepancies in trial results is crucial for optimizing future therapeutic strategies.
- Further research is needed to establish the definitive role and optimal application of renal denervation in managing resistant hypertension.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
01:23Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
01:22Heart Failure Drugs: Diuretics
1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K